+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel



Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel



Molecular Cancer Therapeutics 4(12): 2001-2007



Both fundamental and clinical studies suggest that class III beta-tubulin expression is associated with resistance to taxanes and constitutes a prognostic factor in several solid tumors. In this study, we assessed the prognostic and predictive value of class III beta-tubulin in tumors of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with paclitaxel-based or other regimens that did not include tubulin-binding agents.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011862236

Download citation: RISBibTeXText

PMID: 16373715

DOI: 10.1158/1535-7163.mct-05-0244


Related references

Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clinical Cancer Research 11(15): 5481-5486, 2005

Class III Beta-tubulin Expression in Non-small Cell Lung Cancer: A Predictive Factor for Paclitaxel Response. Anticancer Research 35(5): 2669-2674, 2015

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 64(3): 326-333, 2008

Class III beta-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer. Internal Medicine 48(4): 203-208, 2009

Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy. Anticancer Research 38(3): 1629-1635, 2018

Mp88-02 Expression Of Class Iii Beta-Tubulin Predicts Prognosis In Cisplatin-Resistant Bladder Cancer Patients Receiving Paclitaxel-Based Second-Line Chemotherapy. The Journal of Urology 197(4): e1174-e1175, 2017

Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. Journal of Thoracic Oncology 5(3): 320-325, 2010

Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis. Lung Cancer 77(1): 9-15, 2012

Tumor MET expression profile predicts the outcome of non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors. Thoracic Cancer 5(6): 517-524, 2014

Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer. Pathology International 59(12): 863-867, 2010

Host response to purified protein derivative of tuberculin predicts outcome in patients receiving intra pleural bcg and levamisole for resectable non small cell lung cancer. Proceedings of the American Association for Cancer Research & American Society of Clinical Oncology 21: 230, 1980

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation. Cancer ChemoTherapy and Pharmacology 64(3): 565-573, 2009

Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy. Lung Cancer 74(2): 310-317, 2012

B-tubulin III and not b-tubulin IV expression nor gene alterations predicts paclitaxel resistance in cell lines and breast cancer patients. Proceedings of the American Association for Cancer Research Annual Meeting 44: 1154, 2003

Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bulletin du Cancer 92(2): E25-E30, 2005